CNQX (Synonyms: 6cyano7Nitroquinoxaline2,3dione, FG 9065) |
Catalog No.GC11799 |
AMPA/kainate receptor antagonist
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 115066-14-3
Sample solution is provided at 25 µL, 10mM.
Quality Control & SDS
- View current batch:
- Purity: >98.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Cell experiment: |
CNQX is applied by injecting a bolus into the input line of the chamber over 60 s using a motorized syringe pump. In a subpopulation of neurons, CNQX is bath applied for 5 min. Control injections of physiological saline or vehicle (DMSO) does not alter membrane potential/input resistance during voltage recordings[4]. |
References: [1]. Blake JF, et al. CNQX blocks acidic amino acid induced depolarizations and synaptic components mediated by non-NMDA receptors in rathippocampal slices. Neurosci Lett. 1988 Jun 29;89(2):182-6. |
CNQX (FG9065) is a potent AMPA/kainate receptor antagonist.
In rat hippocampal slices bathed in Mg2+-free medium, 10 μM CNQX reversibly blocks responses to a-amino-3-hydroxy-5-methyl-4-isoxazole-propionic acid (AMPA), quisqualate and kainate but not NMDA[1]. Superfusion of hippocampal slices with 6-cyano-7-nitroquinoxaline-2,3-dione (CNQX, 2-5 μM) reversibly blocks the Schaffer collateral and mossy fibre excitatory postsynaptic potential (EPSP), while sparing the fast and slow GABA-mediated inhibition[2]. CNQX (1-5 μM) produces a selective and dose-dependent reduction in the amplitude of the monosynaptic component of the DR-VRR recorded from lumbar spinal segments[3]. CNQX-mediated depolarizations are mediated by AMPAR but not kainate receptors in TRN neurons[4].
The bilateral infusion of CNQX (0.5 or 1.25 μg) into the amygdala or dorsal hippocampus 10 min prior to a retention test partially blocks the expression of stepdown inhibitory avoidance in rats 24 h after training. CNQX causes a complete blockade at a dose of 0.5 μg[5].
References:
[1]. Blake JF, et al. CNQX blocks acidic amino acid induced depolarizations and synaptic components mediated by non-NMDA receptors in rathippocampal slices. Neurosci Lett. 1988 Jun 29;89(2):182-6.
[2]. Neuman RS, et al. Blockade of excitatory synaptic transmission by 6-cyano-7-nitroquinoxaline-2,3-dione(CNQX) in the hippocampus in vitro. Neurosci Lett. 1988 Sep 23;92(1):64-8.
[3]. Alford S, et al. CNQX and DNQX block non-NMDA synaptic transmission but not NMDA-evoked locomotion in lamprey spinal cord. Brain Res. 1990 Jan 8;506(2):297-302.
[4]. Lee SH, et al. Selective excitatory actions of DNQX and CNQX in rat thalamic neurons. J Neurophysiol. 2010 Apr;103(4):1728-34.
[5]. Kim M, et al. Infusion of the non-NMDA receptor antagonist CNQX into the amygdala blocks the expression of fear-potentiated startle. Behav Neural Biol. 1993 Jan;59(1):5-8.
Cas No. | 115066-14-3 | SDF | |
Synonyms | 6cyano7Nitroquinoxaline2,3dione, FG 9065 | ||
Chemical Name | 7-nitro-2,3-dioxo-1,2,3,4-tetrahydroquinoxaline-6-carbonitrile | ||
Canonical SMILES | O=C1NC2=CC([N+]([O-])=O)=C(C#N)C=C2NC1=O | ||
Formula | C9H4N4O4 | M.Wt | 232.16 |
Solubility | ≥ 23.2mg/mL in DMSO | Storage | Store at -20°C |
General tips | Please select the appropriate solvent to prepare the stock solution according to the
solubility of the product in different solvents; once the solution is prepared, please store it in
separate packages to avoid product failure caused by repeated freezing and thawing.Storage method
and period of the stock solution: When stored at -80°C, please use it within 6 months; when stored
at -20°C, please use it within 1 month. To increase solubility, heat the tube to 37°C and then oscillate in an ultrasonic bath for some time. |
||
Shipping Condition | Evaluation sample solution: shipped with blue ice. All other sizes available: with RT, or with Blue Ice upon request. |
Prepare stock solution | |||
1 mg | 5 mg | 10 mg | |
1 mM | 4.3074 mL | 21.5369 mL | 43.0737 mL |
5 mM | 0.8615 mL | 4.3074 mL | 8.6147 mL |
10 mM | 0.4307 mL | 2.1537 mL | 4.3074 mL |
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.
3. All of the above co-solvents are available for purchase on the GlpBio website.
Average Rating: 5
(Based on Reviews and 9 reference(s) in Google Scholar.)GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *